Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
6990
Rank in Stocks
#1583
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., a biopharmaceutical company,... Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs in oncology, immunology, metabolism, and other therapeutic areas in the People’s Republic of China and internationally. The company’s product pipeline includes Sac-TMT, a novel TROP2 ADC positioned as a monotherapy and part of combination therapies for treating various advanced solid tumors; Trastuzumab botidotin, a monotherapy to treat advanced HER2+ solid tumors; SKB315, a novel CLDN18.2 ADC targeting advanced solid tumors; SKB410/MK-3120, a novel Nectin-4 ADC targeting advanced solid tumors; and SKB571/MK-2750, a novel bsADC primarily targeting various solid tumors, such as LC and CRC. The company also develops SKB518, SKB535/MK-6204 and SKB445, which are novel ADC drugs with potential FIC targets; SKB500 and SKB501, which are novel ADC drugs with verified targets but differentiated payload-linker strategies; SKB107, an RDC targeting tumor bone metastases; Tagitanlimab, PD-L1 mAb for its immunotherapy franchise; Cetuximab N01, a recombinant EGFR human-mouse chimeric mAb; A400, a novel selective RET inhibitor; and A296, a novel small molecule STING agonist. It has license and collaboration arrangements with Merck Sharp & Dohme LLC; Harbour BioMed Therapeutics Limited; Windward Bio AG; and Ellipses Pharma Limited. The company has a strategic partnership with Crescent Biopharma, Inc. The company was incorporated in 2016 and is headquartered in Chengdu, the People’s Republic of China. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd.
Share Price
$57.07
Market Cap
$13.64B
Change (1 day)
-5.37%
Change (1 year)
-2.19%
Country
CN
Trade Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990)
Category
Healthcare
Operating Margin for Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990)
Operating Margin as of October 2026 TTM: 2.49%
According to Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. latest financial reports and stock price the company's current Operating Margin (TTM) is 2.49%. At the end of 2026 the company had an Operating Margin of 0.00%.
Operating Margin history for Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. from 2025 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 2.49% | -110.99% |
| 2025 | -22.65% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -84.50% |
US
|
|
| -149.01% | -159.84% |
US
|
|
| 25.57% | -89.73% |
AU
|
|
| 31.23% | -87.46% |
BE
|
|
| 28.81% | -88.43% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.